Sionna raises $182M for small molecules to aid CFTR function
Sionna Therapeutics has raised $182 million in financing to advance the development of small molecules designed to restore CFTR protein function by binding to a specific part of the protein called the first nucleotide-binding domain, or NBD1. Cystic fibrosis (CF) is caused by mutations in the gene…